Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplantation
Autor: | Stephen J. Forman, Jeffrey Y.C. Wong, Anthony S. Stein, Timothy E. Schultheiss, Joseph Rosenthal, Nicole Tsai, Joycelynne Palmer, An Liu, Ji Hyun Kim |
---|---|
Rok vydání: | 2013 |
Předmět: |
Organs at Risk
Cancer Research Myeloid Transplantation Conditioning medicine.medical_treatment Graft vs Host Disease Bone Marrow Recurrence Prospective Studies Prospective cohort study Child Lymph node Melphalan Etoposide Radiation Age Factors Hematopoietic Stem Cell Transplantation Radiotherapy Dosage Total body irradiation Middle Aged Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia Leukemia Myeloid Acute medicine.anatomical_structure Oncology Radiology Vidarabine Whole-Body Irradiation Adult medicine.medical_specialty Adolescent Antineoplastic Agents Young Adult medicine Humans Radiology Nuclear Medicine and imaging Busulfan Cyclophosphamide Aged Lymphatic Irradiation business.industry medicine.disease Surgery Transplantation Radiation therapy Myelodysplastic Syndromes Bone marrow business Blast Crisis Organ Sparing Treatments |
Zdroj: | International journal of radiation oncology, biology, physics. 89(1) |
ISSN: | 1879-355X |
Popis: | Approximately 5% to 20% of patients who undergo total body irradiation (TBI) in preparation for hematopoietic cell transplantation (HCT) can develop extramedullary (EM) relapse. Whereas total marrow and lymphoid irradiation (TMLI) provides a more conformally targeted radiation therapy for patients, organ sparing has the potential to place the patient at a higher risk for EM relapse than TBI. This study evaluated EM relapse in patients treated with TMLI at our institution.Patients eligible for analysis had been enrolled in 1 of 3 prospective TMLI trials between 2006 and 2012. The TMLI targeted bones, major lymph node chains, liver, spleen, testes, and brain, using image-guided tomotherapy with total dose ranging from 12 to 15 Gy.A total of 101 patients with a median age of 47 years were studied. The median follow-up was 12.8 months. Incidence of EM relapse and bone marrow (BM) relapse were 12.9% and 25.7%, respectively. Of the 13 patients who had EM relapse, 4 also had BM relapse, and 7 had EM disease prior to HCT. There were a total of 19 EM relapse sites as the site of initial recurrence: 11 soft tissue, 6 lymph node, 2 skin. Nine of these sites were within the target region and received ≥12 Gy. Ten initial EM relapse sites were outside of the target region: 5 sites received 10.1 to 11.4 Gy while 5 sites received10 Gy. Pretransplantation EM was the only significant predictor of subsequent EM relapse. The cumulative incidence of EM relapse was 4% at 1 year and 11.4% at 2 years.EM relapse incidence was as frequent in regions receiving ≥10 Gy as those receiving10 Gy. EM relapse rates following TMLI that included HCT regimens were comparable to published results with regimens including TBI and suggest that TMLI is not associated with an increased EM relapse risk. |
Databáze: | OpenAIRE |
Externí odkaz: |